Developers working on methicillin-resistant staphylococcus aureus (MRSA) treatments market are expected to invest resources into research and development activities, for the generation of new product ...

The global Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Industry has valued at US$ 3.9 billion in 2022 and is anticipated to grow to US$ 5.5 billion by 2030, with sales revenue set to ...

A new class of engineered proteins may counter infection caused by Staphylococcus aureus -- a bacterial species considered one of the largest global health threats, a new study suggests. A new class ...

Rising investments in the biopharmaceutical industry in response the coronavirus pandemic, has generated new opportunities for the methicillin-resistant staphylococcus aureus treatment market.

Scientists have found a promising treatment method that in laboratory mice reduces the severity of skin and soft-tissue damage caused by USA300, the leading cause of community-associated ...

Linezolid Nosocomial pneumonia, cSSSI Oral and intravenous form available, bacteriostatic, not approved for catheter-related bloodstream infections, side effects include myelosuppression, ...

Staphylococcus aureus bacteremia and endocarditis are serious infections that demand prompt clinical attention to ensure good outcomes. Of foremost importance is identifying and managing the source of ...

Treating Staphylococcus aureus colonization in patients prior to surgery is a common step to prevent surgical site infections, but patients do not always follow the multistep application instructions ...

A National Institutes of Health (NIH)-supported clinical trial has found that the outcome of treating complicated Staphylococcus aureus bloodstream infections with two intravenous (IV) doses of the ...

As mentioned earlier, there is an urgent need for the development of novel antibiotics targeting S. aureus. Fortunately, a number of new agents active against MRSA and other Gram-positive pathogens ...